Deputy Director:
Jayne Peterson, R.Ph., J.D.
HFD-21, (301) 827-7001

Team Leaders:
LT Cicely Reese, Pharm.D. 
HFD-21, (301) 827-7001
Karen Templeton-Somers, Ph.D.
HFD-21, (301) 827-7001

Lead Public Health Analyst:
Susan Peters
HFD-21, (301) 827-7002
Cynthia Abernethy
HFD-21, (301) 827-7001

Public Health Analysts:
LT Katherine Kim, Pharm.D. (301) 827-7001
Kimberly Kline (301) 827-7001
Cathy Miller  (301) 827-7001
CDR Karen Bryant, R.N. (301) 827-7001
Ji LaRose, Pharm.D. (301) 827-7001
Ahn Vu (301) 827-7001

Project Specialists:
Mary Barnes (301) 827-7002
John Lautmann  (301) 827-7002
Charlene Burroughs (301) 827-7001
Vontina Collick (301) 827-7002
Laurie Davie (301) 827-7002

Health Science Administrator/Data Base Administrator:
LCDR Sohail Mosaddegh, Pharm.D.  (301) 827-7001

Technical Information Specialist:
LCDR Thiep Vo (301) 827-7001

Office Manager:
Chris Shipe  (301) 827-7001

ACS Writer Editor:
Robin Spencer  (301) 827-7001

Anesthetic and Life Support Drugs Advisory Committee

Kalyani Bhatt, B.Sc., M.D.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Anesthesia, Analgesia, and Rheumatology Products
ODE II

Anti-Infective Drugs Advisory Committee

Janie Kim, Pharm.D.
Designated Federal Official
HFD-21,  (301) 827-7001

Division of Anti-Infective and Ophthalmologic Products
ODE IV

Antiviral Drugs Advisory Committee

Paul Tran, R.Ph.
Designated Federal Official
HFD-21 (301) 827-7001

Division of Antiviral Products
ODE IV

Arthritis Advisory Committee

LT Nicole Vesley, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Anesthesia, Analgesia, and Rheumatology Products
ODE II

Cardiovascular and Renal Drugs Advisory Committee

Elaine Ferguson, R.Ph., M.S.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Cardiovascular and Renal Products
ODE I

Dermatologic and Ophthalmic Drugs Advisory  Committee

LT Yvette Waples, Pharm.D.
Designated Federal Official
 HFD-21, (301) 827-7001

Division of Dermatology and Dental Products
ODE III

Drug Safety and Risk Management Advisory Committee

Elaine Ferguson, R.Ph., M.S.
Designated Federal Official
HFD-21, (301) 827-7001

Office of Surveillance and Epidemiology

Endocrinologic and Metabolic Drugs Advisory Committee

Paul Tran, R.Ph.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Metabolism and Endocrinology Products
ODE II

Gastrointestinal Drugs Advisory Committee

Kristine Khuc, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Gastroenterology Products
ODE III

Nonprescription Drugs Advisory Committee

LCDR Diem-Kieu Ngo, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Office of Nonprescription Products

Oncologic Drugs Advisory Committee

LT Nicole Vesley, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Office of Oncology Drug Products

Peripheral and Central Nervous System Drugs Advisory Committee

LCDR Diem-Kieu Ngo, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Neurology Products
ODE I

Pharmaceutical Science, Advisory  Committee

LCDR Sohail Mosaddegh, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Office of Pharmaceutical Science

Psychopharmacologic Drugs Advisory Committee

LT Yvette Waples, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Psychiatry Products
ODE I

Pulmonary-Allergy Drugs Advisory Committee

Kristine Khuc, Pharm.D.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Pulmonary and Allergy Products
ODE II

Reproductive Health Drugs,  Advisory Committee

Kalyani Bhatt, B.Sc., M.S.
Designated Federal Official
HFD-21, (301) 827-7001

Division of Reproductive and Urologic Products
ODE III